



June 29, 2018

**Announcement of an Approval for OPALMON TABLET 5 µg,
an Oral Prostaglandin E₁ Analogue, in Thailand**

Meiji Seika Pharma Co., Ltd. (Tokyo, Japan; President and Representative Director: Daikichiro Kobayashi, “Meiji”) and Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director: Gyo Sagara, “Ono”) announced that a foreign subsidiary of Meiji, Thai Meiji Pharmaceutical Co., Ltd. (Bangkok, Thailand; President: Shinichi Takayama, “Thai Meiji”) has received an approval for OPALMON TABLET 5 µg, an Oral Prostaglandin E₁ Analogue, (Japanese product name: Opalmon Tablet 5 µg, generic name: limaprost alfadex, “limaprost”) for the treatment of thromboangiitis obliterans and lumbar spinal canal from the Thai Food and Drug Administration.

Meiji and Ono signed an agreement on development and commercialization of limaprost in Thailand and Indonesia in July 2014. Thai Meiji submitted an application for limaprost for the treatment of thromboangiitis obliterans and lumbar spinal canal in Thailand. Following the approval in Thailand, Thai Meiji will market limaprost exclusively in Thailand and Ono will assist their promotion activities. Ono will retain the right to co-promote limaprost with Thai Meiji in Thailand.

Meiji and Ono will be committed to bringing limaprost to patients with lumbar spinal canal, as quickly as possible, where no effective treatment drug remains available in Thailand, as well as contributing the treatment in this patient population.

Contacts:

Meiji Seika Pharma Co., Ltd.	Ono Pharmaceutical Co., Ltd.
General Affairs Dept. Public Relations Mail: pr-pharma@meiji.com	Corporate Communications Mail: public_relations@ono.co.jp